文献速递肝病消化道肿瘤与早癌

MASLD/MASH相关肝细胞癌的分子机制

Molecular mechanisms in MASLD/MASH-related HCC.
PubMed 文献 · Hepatology · 2024-02-13

本文综述MASLD/MASH相关肝细胞癌(MASH-HCC)的分子机制。MASLD影响约20%-25%人群,MASH每年约2%进展为MASH-HCC。综述涵盖遗传变异、体细胞突变、多组学、免疫微环境及靶向/联合治疗,旨在推动更有效治疗策略。

要点

  • MASLD影响约20%-25%人群,MASH每年约2%进展为MASH-HCC。
  • MASH-HCC分子与免疫特征区别于其他病因HCC,男女发病率相当。
  • 早期至中期MASH-HCC以手术和局部治疗为主,晚期用系统治疗。

核心结论

  • 深化对MASH-HCC分子机制的理解有望推动更有效治疗策略并改善患者结局。

研究设计与样本

  • 本文为综合性综述,整合既往研究并纳入MASH-HCC分子机制的最新见解。

主要发现

  • MASLD影响约20%-25%的人群,其严重表现MASH每年约2%进展为MASH-HCC。
  • MASH-HCC的发生受遗传突变、致癌物暴露、免疫微环境和微生物组等多种因素影响。
  • MASH-HCC具有区别于其他病因HCC的分子和免疫特征,且男女受累程度相当。

关键数值与推荐

  • 早期至中期MASH-HCC通常采用手术和局部区域治疗。
  • 晚期HCC采用系统治疗,包括抗血管生成治疗和免疫检查点抑制剂。

临床怎么用

  • MASH-HCC早期至中期以手术和局部区域治疗为主,晚期采用含抗血管生成和免疫检查点抑制剂的系统治疗。
  • 关注遗传变异、体细胞突变、多组学、免疫微环境及微生物组以识别治疗应答生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, and its more severe manifestation, NASH or metabolic dysfunction-associated steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% of the population. The increased prevalence of metabolic dysfunction-associated steatotic liver disease and MASH is parallel to the increasing rates of obesity-associated metabolic diseases, including type 2 diabetes, insulin resistance, and fatty liver diseases. MASH can progress to MASH-related HCC (MASH-HCC) in about 2% of cases each year, influenced by various factors such as genetic mutations, carcinogen exposure, immune microenvironment, and microbiome. MASH-HCC exhibits distinct molecular and immune characteristics compared to other causes of HCC and affects both men and women equally. The management of early to intermediate-stage MASH-HCC typically involves surgery and locoregional therapies, while advanced HCC is treated with systemic therapies, including anti-angiogenic therapies and immune checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings while also providing the most current insights into the intricate molecular processes underlying MASH-HCC development. We delve into MASH-HCC-associated genetic variations and somatic mutations, disease progression and research models, multiomics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders. By furthering our comprehension of the molecular mechanisms underlying MASH-HCC, our goal is to catalyze the advancement of more potent treatment strategies, ultimately leading to enhanced patient outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang L, Dong B, et al. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology. 2024. PMID: 38349726. doi:10.1097/HEP.0000000000000786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。